



Management

Byron Hewett, Founder and CEO

Byron founded Brava Diagnostics with MBio in August 2018. Byron has led healthcare and life science companies for more than 30 years, in multi-national firms, development-stage and start-up companies. His expertise is in general management, strategy, business development, sales and marketing.

12/2013 – 4/2017	CEO	SomaLogic	Life sciences tools company focused on biomarker discovery
2008 - 2013	Chairman & CEO	BioBehavioral Diagnostics	Start-up medical device company with the first FDA-cleared system for the assessment of ADHD. The Company was sold to Pearson in August, 2013
2006 - 2008 2004 - 2006	CEO and director President & COO	Immunicon Corp. (NASDAQ: IMMC)	First FDA-cleared test for circulating tumor cells (CTC) for metastatic breast, colorectal and prostate cancer.
2002 - 2004	SVP, Sales & Marketing/GM North America	Qiagen, Inc	Led commercial North American operations
1999 - 2002	VP, U.S. Branch, and VP WW Marketing, LTS	Bayer Diagnostics	Led integration of Chiron into Bayer. Led worldwide marketing for Lab Testing Segment
1998 - 1999	President, U.S. Commercial Operations	Chiron Diagnostics	
Education	Masters in Management, Northwestern University's J.L. Kellogg Graduate School of Management BS, University of Virginia's McIntire School of Commerce		

David Okrongly, Ph.D., Co-Founder and Chief Operating Officer

Dave joined Brava in January 2019. Dave has been a business executive and R&D leader in the diagnostics industry, ranging from start-up to multi-national companies. He brings expertise in instrument and assay development, clinical trials, regulatory affairs and operations.

7/2013 – 11/2018	President	OPKO Diagnostics (OPKO Health, Inc. NYSE: OPK)	Led the development and launch of the 4Kscore test for risk determination of aggressive prostate cancer and development of the Claros 1 point-of-care analyzer utilizing whole blood samples
2011 - 2013	COO	Exosome	An early stage, venture-backed company developing molecular diagnostic tests based on proprietary technology for purifying RNA derived from exosomes.
2009 - 2011	President & CEO	Quanterix Corp. (NASDAQ: QTRX)	Developed single molecule array immunoassay and molecular diagnostic technology
2007 - 2009	Global Head, Molecular Diagnostics	Siemens Healthcare Diagnostics	Managed a global R&D, manufacturing, and CLIA Lab team. Obtained FDA and CE registration for multiple PMA products
1997 - 2006	Global Head of R&D	Bayer Diagnostics	Led global R&D organization of 635 engineers and scientists (\$140M budget)
Education	PhD, Chemistry, Columbia University BSc, University of Wisconsin, Madison		

Carrie Mulherin, Co-Founder and Chief Marketing Officer

Carrie joined Brava Diagnostics in August 2018. She is a marketing and sales executive with extensive start-up experience and 31 product launches. Carrie's expertise is in the diagnostics industry and she brings deep experience with product development teams, clinical development and FDA submissions.

10/2017 – present	CEO	Focus Marketing	Planning, market research, commercial execution
8/2014 – 10/2017	VP of Marketing, Diagnostics	SomaLogic, Inc.	Strategic planning, market assessment, go-to-market plan, reimbursement, product & clinical development teams.
2009 – 2014	VP, Marketing & Sales	BioBehavioral Diagnostics/ Pearson	Start-up. Planning, commercial execution, product development & financing teams.
2008 – 2009	Director of Marketing	OraSure	Rapid infectious disease assays
2002 – 2008	VP, Marketing	Immunicon Corporation	Development-stage cancer Dx (liquid biopsy). Planning, strategic marketing, business development.
2000 – 2002	Director of Marketing	ThauMDx, LLC	Start-up. Multiplex point-of-care cardiac marker and molecular assays.
1997 – 2000	VP, Sales and Marketing	Intracel Corporation	Spin-out from Baxter.
Education	MBA, Marketing, University of Scranton AB, Molecular Biology, Princeton University		

Board of Directors

Robert J. Silverman, Chairman of the Board and Independent Director

Robert J. Silverman is the Board Chairman for Brava Diagnostics. Bob currently serves in a Board and Advisory capacity to a portfolio of companies including MBio Diagnostics, Kiyatec Inc., Lophius Biosciences GmbH, Pathovax LLC and Gilde Healthcare Venture Partners. He served as the CEO of mtm laboratories AG, an in-vitro diagnostics company that developed and commercialized a portfolio of products for the early detection and diagnosis of cervical cancer. Bob was instrumental in raising capital and building mtm laboratories into a global, fully-integrated commercial business. He led the company to a \$240 Million exit to Roche Diagnostics. Prior to leading mtm laboratories, he held senior executive positions at Viacell, Cytoc Corporation, Pasteur Merieux and Abbott Laboratories Pharmaceuticals.

Bob earned his Master's Degree in Marketing and Finance from the Kellogg Graduate School of Management at Northwestern University. He received his B.S. in Pharmacy from the University of Michigan.

Byron Hewett, Chief Executive Officer, Brava Diagnostics

Christopher J. Myatt, Ph.D. Chief Executive Officer, MBio

Dr. Myatt is the founder and CEO of MBio Diagnostics, Inc. He is an entrepreneur with a proven track record for building technology companies, securing patents and licensing technology, raising funding, establishing commercial operations, and leading through growth. Prior to MBio Diagnostics, Chris successfully founded and led Precision Photonics Corporation, a successful laser and optical technology supplier that is now a division of IDEX. Trained as a physicist and measurement scientist, Chris invented and developed multiple technologies that formed the basis of his companies.

Chris earned a B.S. in Physics and a B.A. in Mathematics at Southern Methodist University. He earned a Ph.D. in Atomic Physics at the University of Colorado. He studied Bose-Einstein Condensation (BEC) under Carl Wieman (Nobel Prize, 2001), helping to create the first BEC condensate in the Wieman lab. He also studied quantum information under David Wineland (Nobel Prize, 2012) as a National Research Council (NRC) Postdoctoral Fellow at the National Institute of Standards and Technology (NIST) in Boulder.

Learn More

Please contact Byron Hewett to schedule a meeting. e-mail: BHewett@BravaDx.com • phone: 661-993-4085